News
Organon releases report showcasing progress towards a ‘healthier’ future for women
The new report highlights the company’s efforts to ensure a more sustainable future for women worldwide
The US pharmaceutical company Organon has released its second annual report, showcasing the company’s progress in bridging the gender health gap.
The Environmental, Social, and Governance (ESG) report has highlighted Organon’s progress on its platform, Her Promise, and its related goals, which are in line with the United Nations Sustainable Development Goals (SDGs).
The announcement has shown the company’s commitment to accelerate innovation in women’s health, address gaps and barriers to reduce unplanned pregnancies and ensure a more sustainable future for women worldwide.
Other highlights of Organon’s progress include:
- Completed eight transactions since Organon’s launch in 2021 that allow the company to advance towards its vision of innovating in women’s health, with new assets and investments.
- Helped to prevent an estimated 57 million unplanned pregnancies since the Her Promise Access Initiative programme began.
- Launched Her Plan is Her Power, a three-year, US$30m initiative that aims to expand and accelerate the company’s efforts to help reduce unplanned pregnancies through global advocacy as well as investments in community-driven solutions, in the US, low- and middle-income countries and around the globe.
- Advanced diversity, equity and inclusion within the company by increasing female representation in leadership and completing its first pay equity studies of employees in the company’s largest markets.
- Made progress towards “key” environmental goals, including overall reductions in the energy, waste and water used.
Kevin Ali, Organon CEO, said: “At Organon, our purpose is fuelled by the promise held by the four billion women and girls in the world.
“Alongside our partners, Organon has made measurable gains against our ESG strategy, including innovating for women’s health needs and helping to reduce the number of unplanned pregnancies.
“I am proud of the progress we’ve made and the impact our initiatives are having in creating a better, more equitable world.”
Carrie Cox, board chairman, said: “Organon’s business mission and its ESG strategy are very much linked. Our second ESG report, highlighting the company’s first full year of operations, shows its progress toward important goals.
“We look forward to Organon maintaining this momentum as the company grows and continues to help improve the health of women, their families and their communities.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment